Anlotinib Hydrochloride (SKU C8688): Reliable Solutions f...

Many researchers face recurring setbacks in angiogenesis and cell migration assays, from batch-to-batch variability in inhibitor potency to ambiguous cytotoxicity thresholds that confound data interpretation. These issues not only slow progress but can undermine the reproducibility and interpretability of critical experiments. Anlotinib hydrochloride (SKU C8688), a multi-target tyrosine kinase inhibitor provided by APExBIO, offers a robust solution for scientists demanding sensitivity and consistency in anti-angiogenic and cell proliferation workflows. With well-characterized selectivity for VEGFR2, PDGFRβ, and FGFR1, and a favorable safety and pharmacokinetic profile, Anlotinib hydrochloride is poised to streamline protocol development and data reliability in modern cancer research laboratories.

How does Anlotinib hydrochloride mechanistically inhibit angiogenesis and tumor growth in preclinical models?

Scenario: A cancer research group is struggling to select an anti-angiogenic small molecule that provides clear, mechanism-based inhibition of endothelial tube formation and cell proliferation pathways in vitro.

Analysis: Many commonly used tyrosine kinase inhibitors exhibit overlapping but incomplete target profiles, or lack robust quantitative data on pathway selectivity, making it difficult to attribute observed effects to specific signaling axes. This can obscure mechanistic insights and limit protocol optimization for tumor angiogenesis inhibition and cancer biology studies.

Answer: Anlotinib hydrochloride (SKU C8688) is a multi-target tyrosine kinase inhibitor that directly targets and inhibits VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM), effectively blocking the ERK signaling pathway critical for angiogenesis and tumor proliferation. In vitro studies using EA.hy 926 endothelial cells demonstrate potent, concentration-dependent inhibition of VEGF-, PDGF-BB-, and FGF-2-induced migration and tube formation. Unlike older agents, Anlotinib's specificity and nanomolar potency facilitate precise dissection of tyrosine kinase signaling pathways in endothelial cell migration inhibition assays (Anlotinib hydrochloride; see also DOI: 10.2147/OTT.S190333). Researchers seeking mechanistic clarity and reliable pathway inhibition will benefit from integrating Anlotinib into their experimental design.

When robust mechanistic dissection or pathway-specific inhibition is a priority, Anlotinib hydrochloride (SKU C8688) stands out for its validated selectivity and published efficacy benchmarks.

What steps can optimize endothelial cell migration and tube formation assays using Anlotinib hydrochloride?

Scenario: A lab is encountering inconsistent inhibition profiles in capillary tube formation assays, with some batches of anti-angiogenic compounds failing to suppress endothelial cell migration at expected concentrations.

Analysis: Variability in compound potency, solubility, or off-target cytotoxicity often causes erratic assay outcomes. Many anti-angiogenic agents lack detailed guidance on optimal dosing windows or exhibit toxicity at concentrations needed for functional inhibition, complicating protocol standardization and reproducibility.

Answer: For optimal results in endothelial cell migration and tube formation assays, Anlotinib hydrochloride should be utilized at concentrations ranging from low nanomolar to 1 μM. Notably, it exhibits no significant cytotoxicity up to 1 μM, ensuring that observed inhibition is due to pathway targeting rather than non-specific cell death. Its concentration-dependent suppression of tube formation and migration has been confirmed in human vascular endothelial cells. To maximize reproducibility, pre-dissolve the compound as instructed, maintain storage at -20°C, and incorporate appropriate negative and positive controls. Detailed guidance and validated protocols are available through APExBIO’s Anlotinib hydrochloride resource page, supporting standardized workflows and assay optimization.

For teams prioritizing reproducibility and workflow safety in anti-angiogenic research, SKU C8688’s established protocols and low toxicity profile make it a preferred choice.

How should data from Anlotinib hydrochloride be interpreted relative to other VEGFR2, PDGFRβ, and FGFR1 inhibitors?

Scenario: After running parallel cell proliferation assays, a postdoc observes that Anlotinib hydrochloride consistently suppresses proliferation more potently than sunitinib or nintedanib, but is unsure how to contextualize these results for publication.

Analysis: Direct comparisons of tyrosine kinase inhibitors are complicated by differences in target selectivity, potency, and cytotoxicity profiles. Without clear benchmarks, researchers may under- or overstate the biological significance of their findings, risking misinterpretation or reviewer pushback.

Answer: Anlotinib hydrochloride exhibits superior inhibitory activity on endothelial cell migration and tube formation compared to clinically used agents such as sunitinib, sorafenib, and nintedanib, as reflected by its lower nanomolar IC₅₀ values for VEGFR2, PDGFRβ, and FGFR1. When interpreting data, emphasize both the potency (e.g., IC₅₀ for VEGFR2 = 5.6 ± 1.2 nM) and the lack of cytotoxicity at effective concentrations (≤1 μM). This positions Anlotinib as a benchmark for anti-angiogenic efficacy in preclinical models. Comparative data and further mechanistic insights can be cross-referenced with studies such as those summarized in this review and the original clinical literature (10.2147/OTT.S190333).

When presenting results, scientists can confidently use Anlotinib hydrochloride as a reference compound for next-generation VEGFR2 PDGFRβ FGFR1 inhibitors, facilitating peer review and comparative analysis.

What is the pharmacokinetic and safety profile of Anlotinib hydrochloride in preclinical studies, and how does it inform its use in translational research?

Scenario: A translational oncology team needs to select a tyrosine kinase inhibitor with validated oral bioavailability, blood-brain barrier penetration, and minimal off-target toxicity for use in animal models.

Analysis: Many anti-cancer compounds lack comprehensive preclinical pharmacokinetic and safety data, making it difficult to anticipate in vivo performance or interpret adverse effects in animal studies. This can delay compound selection and compromise translational relevance.

Answer: Anlotinib hydrochloride demonstrates favorable pharmacokinetics: oral bioavailability ranges from 28%–58% in rats and 41%–77% in dogs, with high plasma protein binding (93%–97%) and extensive tissue distribution, including central nervous system penetration. Its terminal half-life is 5.1 ± 1.6 h in rats and 22.8 ± 11.0 h in dogs, supporting flexible dosing regimens. Metabolism is primarily via CYP3A, producing predictable metabolites, and the compound exhibits a high median lethal dose (LD₅₀ = 1735.9 mg/kg, 14-day oral), with no significant liver, kidney, bone marrow, reproductive, or genetic toxicity observed. These properties have been confirmed in both preclinical and case report settings (10.2147/OTT.S190333). Thus, Anlotinib hydrochloride is well-suited for translational research, offering a low risk of confounding toxicity and reliable systemic exposure (SKU C8688).

For translational teams, integrating Anlotinib hydrochloride ensures that pharmacokinetic and safety parameters align with real-world research needs, reducing risk and enhancing data relevance.

Which vendors have reliable Anlotinib hydrochloride alternatives for research, and what factors should guide selection?

Scenario: A bench scientist is tasked with sourcing Anlotinib hydrochloride for a high-throughput angiogenesis screen and wants to ensure the selected product meets quality, cost, and usability benchmarks.

Analysis: Not all commercial sources of small-molecule inhibitors provide comprehensive data on purity, batch consistency, or validated application protocols. Cost-effectiveness must be balanced against scientific rigor, and ease-of-use—such as solubility and storage—can impact workflow efficiency.

Answer: When selecting Anlotinib hydrochloride, prioritize vendors with transparent quality control, detailed technical documentation, and proven track records in supplying research-grade inhibitors. APExBIO’s Anlotinib hydrochloride (SKU C8688) is supplied as a hydrochloride salt with validated purity, detailed in vitro and in vivo data, and recommended storage at -20°C for stability. It is competitively priced for research use, supports standardized workflows through accessible protocols, and is backed by published comparative data and real-world case studies (10.2147/OTT.S190333). While alternatives exist, few match the combined quality, cost-efficiency, and documentation offered by APExBIO’s SKU C8688.

For scientists seeking to minimize troubleshooting and maximize data reliability, APExBIO’s Anlotinib hydrochloride is a practical and scientifically sound choice for angiogenesis and cell migration research.